Clinical Evidence

Outcomes of the md_pereligyn protocol in type 2 diabetes remission

These outcomes are reproducible across 15 years of clinical practice. This is observational clinical data (not a randomized trial): it reflects a consistent association between the protocol and remission and does not replace an individual consultation.

Aggregated outcomes (500+ patients)

Remission defined as HbA1c < 6.5% maintained ≥3 months without glucose-lowering medication. Observational clinical practice, 2010–2026.

Anonymized clinical case (n = 1)

Woman ~44 years old, T2D + non-alcoholic fatty liver disease. Published with the patient’s informed consent; all personal data removed.

Clinical context

• •This illustrates the trajectory in one patient; statistical robustness comes from the aggregate above (500+ observations).
• •The HbA1c trajectory was non-monotonic — an interim rise to ~11.5% before falling to 6.46%.
• •Remission was achieved on combination therapy (lifestyle + metformin + SGLT2 inhibitor + berberine + myo-inositol); the contribution of any single component was not isolated.
• •Treatment de-intensification was required during follow-up due to hypoglycemic episodes; the patient remains under active monitoring.

Methodology and limitations

• —Design: retrospective observational data from a single online practice, without a control group or randomization.
• —Selection and publication bias are possible; outcomes have not been verified by independent audit.
• —Results are individual and depend on diabetes duration, baseline status, and adherence.
• —This material is educational and is not medical advice.

Primary data and sources

Machine-readable aggregate and the full list of peer-reviewed sources: